SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-053614
Filing Date
2020-11-12
Accepted
2020-11-12 16:36:14
Documents
63
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ngm-10q_20200930.htm 10-Q 2708001
2 EX-31.1 ngm-ex311_8.htm EX-31.1 15941
3 EX-31.2 ngm-ex312_9.htm EX-31.2 15930
4 EX-32.1 ngm-ex321_6.htm EX-32.1 8723
  Complete submission text file 0001564590-20-053614.txt   8535933

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT ngm-20200930.xml EX-101.INS 1808167
6 XBRL TAXONOMY EXTENSION SCHEMA ngm-20200930.xsd EX-101.SCH 54937
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ngm-20200930_cal.xml EX-101.CAL 41789
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ngm-20200930_def.xml EX-101.DEF 193517
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE ngm-20200930_lab.xml EX-101.LAB 435275
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ngm-20200930_pre.xml EX-101.PRE 334826
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38853 | Film No.: 201307336
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences